Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 121044 results found since Jan 2013.
Investigating the heat sensitivity of frequently used excipients with varying particle sizes
Eur J Pharm Biopharm. 2023 Sep 14:S0939-6411(23)00243-6. doi: 10.1016/j.ejpb.2023.09.010. Online ahead of print.ABSTRACTDuring tablet manufacturing an increase in the production temperature can lead to an alteration of tablet characteristics. In the present study, the influence of the initial particle size on the tableting behavior of ductile polymers upon temperature rise was investigated. Different grades of the respective materials were tableted at temperatures ranging from 22-70 °C. Alterations in tableting behavior were affected by the initial particle size. Smaller particle sizes led to a more pronounced decrease in...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Hanna Dorothea Grumann Peter Kleinebudde Source Type: research
Telocytes protect against lung tissue fibrosis through hexokinase 2-dependent pathway by secreting hepatocyte growth factor
In conclusion, TCs can protect against lung tissue fibrosis by releasing HGF, a process dependent on HK2.PMID:37715611 | DOI:10.1111/1440-1681.13823
Source: Clinical and Experimental Pharmacology and Physiology - September 16, 2023 Category: Drugs & Pharmacology Authors: Shaoyuan Zhang Linyi Sun Borong Chen Siyun Lin Jianmin Gu Lijie Tan Miao Lin Source Type: research
Investigating the heat sensitivity of frequently used excipients with varying particle sizes
Eur J Pharm Biopharm. 2023 Sep 14:S0939-6411(23)00243-6. doi: 10.1016/j.ejpb.2023.09.010. Online ahead of print.ABSTRACTDuring tablet manufacturing an increase in the production temperature can lead to an alteration of tablet characteristics. In the present study, the influence of the initial particle size on the tableting behavior of ductile polymers upon temperature rise was investigated. Different grades of the respective materials were tableted at temperatures ranging from 22-70 °C. Alterations in tableting behavior were affected by the initial particle size. Smaller particle sizes led to a more pronounced decrease in...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Hanna Dorothea Grumann Peter Kleinebudde Source Type: research
Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders
Neuropharmacology. 2023 Sep 14;240:109715. doi: 10.1016/j.neuropharm.2023.109715. Online ahead of print.ABSTRACTMaternal immune activation (MIA) resulting from viral infections during pregnancy is linked to increased rates of neurodevelopmental disorders in offspring. However, the mechanisms underlying MIA-induced neurobehavioral abnormalities remain unclear. Here, we used a poly (I:C)-induced MIA mouse model to demonstrate the presence of multiple behavioral deficits in male offspring. Through RNA sequencing (RNA-seq), we identified significant upregulation of genes involved in axonogenesis, synaptogenesis, and glutamater...
Source: Neuropharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Lu Zhang Chunqiao Lin Jiushuang Zhu Yan He Meng Zhan Xiuwen Xia Ni Yang Kun Yang Baojia Wang Zhanqion Zhong Yili Wang Weijun Ding Youjun Yang Source Type: research
Translated article Medication reconciliation in pediatric hemato-oncologic patients: A multicenter study
CONCLUSIONS: In order to avoid or reduce errors in one of the critical safety points such as transitions of care, there are measures such as medication reconciliation. In the case of complex chronic pediatric patients, such as onco-hematological patients, the number of drugs as part of home treatment is the variable that has been associated with the presence of medication reconciliation errors on admission to hospital, and the omission of some medication was the main cause of these errors.PMID:37716875 | DOI:10.1016/j.farma.2023.07.012
Source: Farmacia Hospitalaria - September 16, 2023 Category: Drugs & Pharmacology Authors: Margarita Cuervas-Mons Vendrell Dolores Pilar Iturgoyen Fuentes Miquel Villaronga Flaque Maria Jos é Cabañas Poy Cecilia M Fern ández-Llamazares Concha Álvarez Del Vayo Carmen Gallego Fern ández Cristina Mart ínez Roca Yolanda Hern ández Gago Ana G Source Type: research
Enthesitis in Spondyloarthritis Including Psoriatic Arthritis-To Inject or Not To Inject?: A Narrative Review
Clin Ther. 2023 Sep 14:S0149-2918(23)00303-X. doi: 10.1016/j.clinthera.2023.08.002. Online ahead of print.ABSTRACTPURPOSE: Enthesitis is a key manifestation of psoriatic arthritis (PsA) and spondyloarthritis (SpA) and is considered to be the tissue where the disease initiates. Enthesitis leads to pain and substantial limitations in patients with PsA. Treatment is key in achieving remission or minimal disease activity. Whether it is safe to apply injections to entheseal tissue is unknown. This narrative review aimed to summarize the literature on the efficacy and tolerability of entheseal corticosteroid (CS) injections.METH...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Ozun Bayindir Tsechelidis Ricardo Sabido-Sauri Sibel Zehra Aydin Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders
Neuropharmacology. 2023 Sep 14;240:109715. doi: 10.1016/j.neuropharm.2023.109715. Online ahead of print.ABSTRACTMaternal immune activation (MIA) resulting from viral infections during pregnancy is linked to increased rates of neurodevelopmental disorders in offspring. However, the mechanisms underlying MIA-induced neurobehavioral abnormalities remain unclear. Here, we used a poly (I:C)-induced MIA mouse model to demonstrate the presence of multiple behavioral deficits in male offspring. Through RNA sequencing (RNA-seq), we identified significant upregulation of genes involved in axonogenesis, synaptogenesis, and glutamater...
Source: Neuropharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Lu Zhang Chunqiao Lin Jiushuang Zhu Yan He Meng Zhan Xiuwen Xia Ni Yang Kun Yang Baojia Wang Zhanqion Zhong Yili Wang Weijun Ding Youjun Yang Source Type: research
Investigating the heat sensitivity of frequently used excipients with varying particle sizes
Eur J Pharm Biopharm. 2023 Sep 14:S0939-6411(23)00243-6. doi: 10.1016/j.ejpb.2023.09.010. Online ahead of print.ABSTRACTDuring tablet manufacturing an increase in the production temperature can lead to an alteration of tablet characteristics. In the present study, the influence of the initial particle size on the tableting behavior of ductile polymers upon temperature rise was investigated. Different grades of the respective materials were tableted at temperatures ranging from 22-70 °C. Alterations in tableting behavior were affected by the initial particle size. Smaller particle sizes led to a more pronounced decrease in...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Hanna Dorothea Grumann Peter Kleinebudde Source Type: research
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
The objective of this study was to characterize clinician response following standardization of pharmacogenetic (PGx) clinical decision support alerts at University of Florida (UF) Health. A retrospective analysis of all PGx alerts that fired at a tertiary academic medical center from August 2020 through May 2022 was performed. Alert acceptance rate was calculated and compared across six gene-drug pairs, patient care setting, and clinician specialty. The disposition of the triggering medication was compared to the alert response and evaluated for congruence. There were a total of 818 alerts included for analysis of alert r...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Lauren K Lemke Emily J Cicali Roy Williams Khoa A Nguyen Larisa H Cavallari Kristin Wiisanen Source Type: research
Ethical Requirements for Human Challenge Studies: A Systematic Review of Reasons
Clin Pharmacol Ther. 2023 Sep 16. doi: 10.1002/cpt.3054. Online ahead of print.ABSTRACTHuman challenge studies (HCS) are controlled clinical trials in which participants are deliberately infected with a pathogen. Such trials are being developed for an increasing number of diseases. Partly as a result of the COVID-19 pandemic, there has been a recent ethical debate about the reasons for and against HCS in general, or rather, about the requirements that individual HCS must fulfill to be ethically acceptable. A systematic review was conducted to categorize and summarize such requirements and the reasons given for them. Ethics...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Matthias Katzer Sabine Salloch Christoph Schindler Marcel Mertz Source Type: research
Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation & amp; Quality (IQ) Consortium Perspective on Use Cases and Best Practices
Clin Pharmacol Ther. 2023 Sep 16. doi: 10.1002/cpt.3053. Online ahead of print.ABSTRACTRecent breakthroughs in Artificial Intelligence (AI) and Machine Learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise is model-informed drug discovery and development (MID3). To foster a wider adoption and acceptance of these advanced algorithms, the Innovation & Quality (IQ) Consortium initiated the AI/ML working group (WG) in 2021 with the aim of promoting their acceptance among the broader scientific community as well as by regulatory...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Nadia Terranova Didier Renard Mohamed H Shahin Sujatha Menon Youfang Cao Cornelis E C A Hop Sean Hayes Kumpal Madrasi Sven Stodtmann Thomas Tensfeldt Pavan Vaddady Nicholas Ellinwood James Lu Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
